News for Daré Bioscience, Inc. (DARE)

Daré Bioscience, Inc. (NASDAQ:DARE) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ETCompany ParticipantsMarDee Haring-Layton - Chief Accounting...

In addition to its proprietary Sildenafil Cream formulation, Daré is taking action to make three other solutions for women available commercially, two vaginal

SAN DIEGO, May 06, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. ( DARE), a biopharmaceutical company driven by a mission to challenge the status quo, makin

Presentation will focus on corporate communications strategies for unveiling an innovative expanded business strategyDaré recently announced its new dual-path

Daré Bioscience's Q4 2024 earnings highlight a dual-path strategy for Sildenafil Cream, targeting 2025 revenue with 503B compounding while advancing FDA...

SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. ( DARE), a leader in innovation for the health and well-being of women, will host a conf

**media[568943]**

**media[534060]**

**media[510775]**

The panel will discuss the value proposition for investing in women's health. J.P. Morgan is hosting a three-panel women's health series at this year's confere

FSAD is clinically analogous to erectile dysfunction in men.To date, there are no FDA-approved pharmacological treatments for FSAD; Daré's Sildenafil Cream has

**media[483210]**

Daré Bioscience's DARE-LARC1 Platform Technology has Transformative Potential for Women's Health as well as in Treating a Broad Range of Diseases Strategic P

Daré Bioscience, Inc. (NASDAQ:DARE) Q3 2024 Earnings Conference Call November 14, 2024 4:30 PM ETCompany ParticipantsMarDee Haring-Layton - CAOSabrina...

Daré Bioscience Reports Third Quarter 2024 Financial Results and Provides Company Update

Daré Bioscience secures $10.7 million grant from Gates Foundation

**media[445119]**

Loading... Loading... Shares of James Hardie Industries plc JHX fell sharply during Tuesday's session after the company reported worse-than-expected quarterly ...

Earned $9 million milestone upon U.S. Food and Drug Administration’s approval of Day One’s OJEMDA™ (tovorafenib); XOMA is entitled to receive a mid-single...